Fanchuang Medical Biotechnology Co., Ltd.

 

Customer Demand Is The Best Source Of Innovation

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsPharmaceutical Intermediates

CAS 220127-57-1 Active Pharmaceutical Ingredients Imatinib Mesylate White powder

Great Service Great Quality.

—— Carl Balfou

I appreciate you because you are so friendly and helpful. You really are a real pleasure to work with so polite and enjoyable to work with.

—— Jeff Rader

You are the sweetest, most caring service possible.

—— Luis Acosta

I'm Online Chat Now

CAS 220127-57-1 Active Pharmaceutical Ingredients Imatinib Mesylate White powder

Large Image :  CAS 220127-57-1 Active Pharmaceutical Ingredients Imatinib Mesylate White powder

Product Details:

Place of Origin: China
Brand Name: R&M
Certification: ISO 9001, USP, GMP
Model Number: 01

Payment & Shipping Terms:

Minimum Order Quantity: 1g
Price: negotiation
Packaging Details: vaccum packing of aluminum foil bag
Detailed Product Description
CasNo: 152459-95-5 Appearance: White Crystalline Powder
Molecular Formula: C30H35N7O4S PackAge: According To The Clients Requirement
Stock: Mass Stock Name: Imatinib Mesylate

Active Pharmaceutical Ingredients CAS 220127-57-1 Imatinib Mesylate White powder

 

Imatinib Mesylate Basic information

 

Product Name Imatinib Mesylate
Alias Imatinib Methanesulfonate, STI-571, CGP-57148B, Glivec
CAS 220127-57-1
MF C30H35N7O4S
MW 589.71
Purity 99.50%
Grade Pharmaceutical Grade
Appearance white Crystalline Powder
Brand Nmae HKYC
Standard USP
Stock Mass Stock
Shelf Life 2years
Packing Methods foil bag or as your mind
Delivery time within 18 hours after payment confirmed
Payment T/T, Western Union,Money Gram , Bitcoin
Usage Imatinib Mesylate is mainy used for anti tumor
Imatinib Mesylate is a tyrosine kinase inhibitor

 

Imatinib Mesylate Product Description

 

Imatinib mesylate is a tyrosine kinase inhibitor IC50 value of 100 nM, 100 nM, 600 nM for v-Abl, c-kit, PDGFR, respectively.

 

Imatinib Mesylate is a specific tyrosine kinase (abl, c-kit, and PDGFR) inhibitor and is reported to sensitize cells to radio- or chemo-therapy. When tested with Y-79 and WERI-RB-1 Rb cell lines, imatinib mesylate treatment decreased the cell proliferation and invasion with the concentration of 10 μM . In osteoblast cells, administration of imatinib mesylate decreased osteoclast development via stimulating differentiation, inhibiting proliferation and survival .

 

In dog model with mast cell tumor, administration of imatinib mesylate at a dose of 10 mg/kg daily for 1-9 weeks reduced tumor growth via inhibiting tyrosine kinase .

 

Imatinib Mesylate Applications

 

Cells were stimulated with allogeneic mature DCs or PHA in the presence of imatinib mesylate. The drug inhibited T-cell proliferation as a function of concentration. The effects were significant at 0.5 μM imatinib mesylate for the cells stimulated by DCs and at 1.0 μM imatinib mesylate for the cells stimulated with PHA. The IC50 values for imatinib mesylate-inhibited T-cell proliferation stimulated by DCs and PHA were 3.9 μM and 2.9 μM, respectively..

 

A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL)

 

Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib

 

Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.

 

echinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis

 

Dosage

 

Starting dose: in patients with chronic myelogenous leukemia radically increasing stage and accelerating stage, imatinib mesylate in the recommended dose of 600 mg/day; Chronic-phase of interferon treatment failure, and cannot be removed surgically or metastatic malignant gastrointestinal stromal tumors (GIST) patients, and the recommended dose of 400 mg/day, both for once-daily oral, appropriate medication when eating, and drinking a glass of water, as long as effective, should be continued.

Contact Details
Fanchuang Medical Biotechnology Co., Ltd.

Contact Person: admin

Send your inquiry directly to us Message not be empty!